Australian University Rankings Guide

MedChemComm (ERA Journal)

MedChemComm is an ERA accredited research journal used as part of the evaluation of the ERA research rankings.

MedChemComm issns are issn1: 2040-2503 issn2: 2040-2511.

The fields covered by MedChemComm as part of the evaluation of Australian university research excellence are:

Medicinal and Biomolecular Chemistry Research Rankings (Sub-Field)

Organic Chemistry Research Rankings (Sub-Field)

Pharmacology and Pharmaceutical Sciences Research Rankings (Sub-Field)

Other ERA-accredited journals supporting the evaluation of the Medicinal and Biomolecular Chemistry field include:

- ACS Medicinal Chemistry Letters
- Advances in Carbohydrate Chemistry and Biochemistry
- Anti-Cancer Agents in Medicinal Chemistry
- Bioorganic Chemistry
- ChemBioChem: a European journal of chemical biology
- Current Protein and Peptide Science
- Drugs in R and D
- European Journal of Medicinal Plants
- Journal of Carbohydrate Chemistry
- Journal of Clinical Biochemistry and Nutrition
- Mass Spectrometry Reviews
- Medicinal Chemistry Research
- Molecular Medicine Reports
- Tetrahedron Letters: the international journal for the rapid publication of all preliminary communications in organic chemistry
- Tetrahedron: the international journal for the rapid publication of full original research papers and critical reviews in organic chemistr


ERA Research Rankings Submenu


- ERA 2018 Outcomes Research Rankings List

- ERA 2018 Research Rankings Analysis

- ERA 2018 Individual University Outcomes List

- ERA List of Research Fields Rankings

- ERA Journal Rankings 2018 List



Latest News and Updates:


- Top 10 Best Australian Universities

- Gender Balance Male-Female Ratio

- ERA 2018 Outcomes Research Rankings List

- University Bachelor Degree Completion Rates

- QS Employability Rankings Australian Universities

- ARWU World Rankings of Australian Universities

- Group of Eight (go8) World Rankings

Share This Page

  • Share on Facebook1
  • Share on Twitter2
  • Share on Linkedin3
  • Share on Reddit4